Mesoblast Ltd Up 6.5% on Heart Failure Trial

Mesoblast Ltd [ASX:MSB] climbed 6.5% this morning, to a high of $2.60 per share. The rally added as much as $70 million to the biotech’s market cap.

What happened to the Mesoblast share price?

MSB develops cell-based medicines. One of their lead product candidates is MPC-150-IM, which is designed to treat chronic congestive heart failure. The product is still in trial phase.

It was an announcement about MPC-150-IM which spiked MSB’s share price this morning. MSB announced that MPC-150-IM was successful in Phase 3 trials. Phase 3 trials measure the effectiveness of a drug or product.

Dr Emerson C Perin, lead investigator for the ongoing trial said:

It is very pleasing to see that this large and rigorously conducted Phase 3 trial of Mesoblast’s cell therapy was successful in the pre-specific interim futility analysis for the trial’s efficacy endpoint in the first 270 patients.

What now for MSB shares?

In 2016, more than 15 million people suffered from chronic congestive heart failure. If you were going to invest in MSB based on MPC-150-IM, it’s important to know there’s a big addressable market.

But this information doesn’t mean you should invest in MSB.

You should look at MSB’s complete operations, rather than a single drug or product. Yet, if you believe MPC-150-IM will contribute to a significant increase in revenues and profits, you might want to take a close look at MSB as an investment.


Härje Ronngard,

Junior Analyst, Money Morning

PS: A majority of wealth in the stock market is made while sitting. If you want to earn massive, reliable returns, you need to invest, not trade.

It sounds easy, but, in reality, profiting from stocks isn’t always smooth sailing. You need to be sitting on the right stocks with huge earnings potential at the right price.

Income specialist Matt Hibbard is a master when it comes to picking undervalued stocks. Matt follows a simple method. He looks for stocks trading below their intrinsic value, but which also pay a hefty dividend.

To find out more, click here.

Money Morning is Australia’s most outspoken financial news service. Your Money Morning editorial team are not afraid to tell it like it is. From calling out politicians to taking on the housing industry, our aim is to cut through the hype and BS to help you make sense of the stories that make a difference to your wealth. Whether you agree with us or not, you’ll find our common-sense, thought provoking arguments well worth a read.

Money Morning Australia is published by Fat Tail Investment Research, an independent financial publisher based in Melbourne, Australia. As an Australian financial services license holder we are subject to the regulations and laws of Corporations Act and Financial Services Act.

Money Morning Australia